This brings the number of doses ordered by the bloc up to 600 million, and is the largest cumulative supply agreement that Pfizer/BioNTech have made globally.
A total of 600 million doses represents enough to cover 300 million people: around two-thirds of the EU population. The vaccine will be supplied from BioNTech and Pfizer’s manufacturing sites in Europe.
Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “To date, we have met all of our supply commitments to the EC and we plan to deliver 250 million doses to the European Union in Q2, a four-fold increase on Q1’s agreed quantity.”
Meanwhile, the EU and Pfizer/BioNTech are in negotiations for a new long-term contract, which would see delivery of 1.8 billion doses between 2021 and 2023.